Circulating Tumour Cells as Surrogate Biomarkers in Castration-Resistant Prostate Cancer Trials
- 30 November 2011
- journal article
- editorial
- Published by Elsevier in European Urology
- Vol. 60 (5) , 905-907
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone AcetateEuropean Urology, 2011
- Circulating Tumor Cells as Biomarkers in Prostate CancerClinical Cancer Research, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Confirmation of the Association of TMPRSS2(exon 0):ERG Expression and a Favorable Prognosis of Primary Prostate CancerEuropean Urology, 2011
- Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate CancerCancer Research, 2009
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009
- Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate CancerClinical Cancer Research, 2007
- Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant DiseasesClinical Cancer Research, 2004
- Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate CancerJournal of Clinical Oncology, 2003